Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient

Background: Paliperidone palmitate has been associated with serum prolactin elevations in some patients. However, few individuals with elevated prolactin levels (hyperprolactinomia) have symptomatic potentially prolactin-related adverse events (PPR-AEs). Objective: To quantify rates of hyperprolactinemia in subjects treated with the newly marketed paliperidone palmitate long-acting injection (PP-LAI) in randomized clinical trials, summarize rates of PPR-AEs in those trials by sex and dose, and determine how many PPR-AEs required treatment. Methods: Numbers and rates of investigator-reported hyperprolactinemia and PPR-AEs wore obtained from the sponsor's clinical trial database and have been included in regulatory filings. Results were tabulated for males, females, and overall, and by dose administered, using descriptive statistics. Those requiring treatment were described as well. Results: There were 3173 subjects (61.4% males) exposed to PP-LAI in 10 clinical trials; 2831 (89.2%) patients had recorded prolactin levels, including 1759 males (90, 3% of exposed males) and 1072 females (87.5% of exposed females). Overall, at any time, prolactin levels were elevated for 38.8% of the subjects (39.5% for males and 37.7% for females; p = 0.354 between sexes). However, them was no significant correlation between monthly dose and proportion of subjects with elevated prolactin levels (p = 0.109). There were 115 PPR-AEs in 107 patients (3.4%); 51 (44.3% of PPR-AEs) cases represented asymptomatic hyperprolactinemia. The remaining 64 symptomatic PPR-AEs affected 2.0% of the total number of subjects. Fifteen events in 13 participants (0.41% of patients or 4.7 events/1000 patients) required treatment. Conclusions: Clinicians should periodically assess patients on paliperidone palmitate for any PPR-AEs and carefully assess the benefits and risks when managing these effects.

Download Full-text

Drug information update: paliperidone palmitate for schizophrenia

The Psychiatrist ◽

10.1192/pb.bp.113.042739 ◽

2013 ◽

Vol 37 (5) ◽

pp. 164-166 ◽

Cited By ~ 2

Author(s):

Abraham M. Nussbaum ◽

T. Scott Stroup

Keyword(s):

Side Effects ◽

Optimal Dose ◽

Paliperidone Palmitate ◽

Serum Prolactin ◽

Sexual Side Effects ◽

Study Results ◽

The Us ◽

Reported Study ◽

Information Update ◽

Long Acting

Aims and methodTo review the evidence for the use of paliperidone palmitate for people with schizophrenia and schizophrenia-like illnesses. We searched the Cochrane Schizophrenia Group Specialised Register and contacted the manufacturer of paliperidone palmitate, the US Food and Drug Administration, and the authors of papers that reported study results.ResultsBased on the evidence from five short-term, placebo-controlled studies, paliperidone palmitate is efficacious as an antipsychotic. Its adverse effects are similar to those of the closely related compounds paliperidone and risperidone. Extrapyramidal side-effects, weight gain and tachycardia are more common with paliperidone palmitate than placebo. Paliperidone palmitate was associated with substantial increases in serum prolactin but not with increased sexual side-effects in these studies. In two studies paliperidone palmitate was similar to depot risperidone.Clinical implicationsPaliperidone palmitate is an effective antipsychotic whose optimal dose appears to be between 39 and 234 mg every 4 weeks. We have no data assessing its long-term effectiveness or comparing it with any long-acting injected antipsychotic other than depot risperidone.

Download Full-text

Prospective analysis of serum prolactin levels, clinical symptomatology and sexual functions in patients with schizophrenia switched to paliperidone palmitate 3‐monthly from paliperidone palmitate 1‐monthly: Preliminary findings of the first 3 months

Human Psychopharmacology Clinical and Experimental ◽

10.1002/hup.2827 ◽

2021 ◽

Author(s):

Ersin Hatice Karslioğlu ◽

Zeynep Kolcu ◽

Nisa İrem Karslioğlu ◽

Ali Çayköylü

Keyword(s):

Paliperidone Palmitate ◽

Serum Prolactin ◽

Prospective Analysis ◽

Clinical Symptomatology

Download Full-text

Spatial context learning and switching strategy

PsycEXTRA Dataset ◽

10.1037/e527352012-849 ◽

2006 ◽

Author(s):

Nobutaka Endo ◽

Walter R. Boot ◽

Arthur F. Kramer ◽

Alejandro Lleras ◽

Takatsune Kumada

Keyword(s):

Spatial Context ◽

Switching Strategy ◽

Context Learning

Download Full-text

SERUM PROLACTINE LEVEL IN PATIENTS OF PSORIASIS VULGARIS AND ITS CORRELATION WITH DISEASE SEVERITY: A CASE-CONTROL STUDY

International Journal of Medical and Biomedical Studies ◽

10.32553/ijmbs.v3i6.303 ◽

2019 ◽

Vol 3 (6) ◽

Author(s):

Pawan Kumar Saini ◽

Devendra Yadav ◽

Rozy Badyal ◽

Suresh Jain ◽

Arti Singh ◽

...

Keyword(s):

Disease Severity ◽

Prolactin Level ◽

Case Control Study ◽

Statistical Significance ◽

Case Control ◽

Serum Prolactin ◽

P Value ◽

Serum Prolactin Level ◽

R Value ◽

Control Study

Background: Psoriasis is an autoimmune chronic inflammatory disorder affecting the skin mediated by T-lymphocytes resulting in production of cytokines which cause hyperproliferation of keratinocytes. Several factors and hormones like Prolactin have an action similar to these cytokines in promoting the multiplication of keratinocytes and other cells like lymphocytes and epithelial cells may have a role on the etiopathogenesis of psoriasis. Aim:-The aim of study is to compare the serum Prolactin levels in patients of psoriasis with a control group. Setting and study design: This is a case-control study conducted in the department of Dermatology, Venereology and Leprosy GMC, Kota over a period of 1year from July 2017 to June 2018 Material and method: The study included 100 cases of psoriasis (60 males and 40 females) and 100 controls similar for age and sex. Serum Prolactin levels were measured by ECLIA and results were obtained. Statistical analysis: Mean and standard deviation were calculated for each variable. Statistical significance of the results was analyzed using correlation analysis (Pearson correlation coefficient) and independent samples t-test. Statistical significance was assumed at p value<0.05. Result: Serum Prolactin level was significantly higher in cases of psoriasis compared to controls (p-value <0.001). PASI score and serum Prolactin levels were found to have a positive correlation (r value = 0.337; p-value: 0.001). No significant correlation was found between serum levels of Prolactin and duration of disease r value= -0.034, P value =0.733). Serum Prolactin level was higher in male patients compared to females patients. Conclusion:- High serum Prolactin may be a biological marker of disease severity in psoriasis and may have a role in the pathogenesis of psoriasis. Further studies with large sample size are required to confirm this hypothesis.

Download Full-text

The correlation between the sociodemographic characteristics and some hormones with the infertility of women and men

Al Mustansiriyah Journal of Pharmaceutical Sciences ◽

10.32947/357 ◽

2018 ◽

Vol 18 (1) ◽

pp. 1-10

Keyword(s):

Soft Drink ◽

Serum Prolactin ◽

Age Group ◽

Tea Consumption ◽

Obese Women ◽

Overweight Women ◽

Infertile Women ◽

Infertile Men ◽

Overweight Group ◽

Prolactin Hormone

Thirty three infertile women were divided into two groups according to their BMI (21 obese and 12 overweight) there age ranges between (16-41) years, with their husbands twenty one infertile men and twelve fertile men and their ages range between (23-46) years. In the present study we observed that several indicators affect the fertility such as BMI in infertile obese women which was 34.65 kg/m2. That is higher than that of overweight infertile women that recorded 24.87 kg/m2. obese housewives scored the highest percentage (85.71%) compared with the overweight group (25%), In addition the obese age group between 30-41 years scored (66.67%) compared with the overweight group whose members’ age 16-29.9 years scored 75%. However, drinking cola (soft drink) percentage in obese infertile women was (85.71%) and the tea consumption was higher in overweight group (66.67%). The hormones FSH and LH decrease in obese women but serum prolactin hormone increased twice about 29.27 ng/ml in comparison with overweight group. Testosterone hormone decreased in obese women but Leptin in obese women (19.52 μg/L) was higher than that of overweight women (11.03 μg/L). Infertile unemployed men got the highest percentage of 66.67%. Besides, the smoker infertile men were higher in percentage (80.95%) compared with fertile men 41.67%. The elevated LH, FSH and prolactin values are significantly high (p<0.01) (7.895 mlU/ml, 9.89 mlU/ml and 13.33 ng/ml) respectively, but the testosterone was significantly low (3.91 ng/dl) in comparison with fertile men(21.76ng/dl). Whileleptin significantly increased in infertile men more than the fertile ones. These changes in hormones have a great correlation with semen characteristics as the abnormalities in sperms increased to (64.52) and the percentage of rapid, progressive and non -progressive motility decreased, but the immotile motility was highly significant (65.71) in infertile men. As a result this indicates that the reason of infertility is shared between the wife and husband.

Download Full-text

Rapid Rechallenge with Clozapine Following Pronounced Myocarditis in a Treatment-Resistant Schizophrenia Patient

Clinical Schizophrenia & Related Psychoses ◽

10.3371/1935-1232-10.2.120 ◽

2016 ◽

Vol 10 (2) ◽

pp. 120-122 ◽

Cited By ~ 8

Author(s):

Pichai Ittasakul ◽

Anthony Archer ◽

Jennifer Kezman ◽

Wanlop Atsariyasing ◽

Morris B. Goldman

Keyword(s):

Schizophrenia Patient ◽

Treatment Resistant

Download Full-text

Pituitary responses to a dopamine antagonist at different times of the day in normal women

Acta Endocrinologica ◽

10.1530/acta.0.1000481 ◽

1982 ◽

Vol 100 (4) ◽

pp. 481-485 ◽

Cited By ~ 5

Author(s):

F. R. Pérez-López ◽

C. M. González-Moreno ◽

M. D. Abós ◽

J. A. Andonegui ◽

R. H. Corvo

Keyword(s):

Serum Prolactin ◽

Dopamine Antagonist ◽

Hormonal Changes ◽

Healthy Women ◽

Serum Lh ◽

Normal Women ◽

The Times ◽

Serum Tsh

Abstract. In order to determine whether or not pituitary responsiveness to the dopaminergic antagonist clebopride changes during the nyctohemeral cycle, 10 healthy women with regular cycles were given 1 mg of clebopride orally at 09.00 h and 24.00 h with at least a 5 day interval between each test. In addition, 5 of the women were given a placebo instead of clebopride at midnight to evaluate the spontaneous hormonal changes. During the 24.00 h test the women had significantly higher P < 0.05) mean TSH basal levels. Serum prolactin (Prl) increased significantly (P < 0.001) after clebopride administration while these changes did not occur when placebo was used instead of clebopride at midnight. The Prl response to clebopride was qualitatively similar at 09.00 h and at 24.00 h. Clebopride given at midnight induced a significant increase (P < 0.05) in serum TSH while this change did not occur when the drug was given at 09.00 h or when placebo was given at midnight. The administration of clebopride resulted in no discernible alterations in serum LH, FSH or GH in either the 09.00 h or the 24.00 h tests. Thus, Prl responses to clebopride were similar in the morning and at midnight, TSH significantly increased after clebopride at midnight whereas this did not occur when the drug was given in the morning, and no significant changes were induced in LH, FSH or GH at the times studied.

Download Full-text

Effect of prolactin inhibition under heat exposure on water intake and excretion of urine, sodium and potassium in bulls

Acta Endocrinologica ◽

10.1530/acta.0.0940315 ◽

1980 ◽

Vol 94 (3) ◽

pp. 315-320 ◽

Cited By ~ 8

Author(s):

D. Schams ◽

E. Stephan ◽

R. D. Hooley

Keyword(s):

Water Intake ◽

Heat Exposure ◽

Physiological Role ◽

Treated Group ◽

Serum Prolactin ◽

Control Value ◽

Light Regimen ◽

Group I ◽

Urinary Potassium ◽

Group Ii

Abstract. Six Holstein bulls were housed in a climate-chamber under constant light regimen and after two weeks of preconditioning at 15°C, 60% relative humidity RH (day) and 12°C, 60% RH (night) were subjected to two weeks of heat exposure. This involved one week at 30°C and 60% RH (day) and 25°C and 60% RH (night) and a further week at 35°C, 60% RH (day) and 30°C, 60% RH (night). Three bulls were untreated (group I) and 3 bulls were treated (group II) just before and during heat exposure with a prolactin inhibitor to study the possible physiological role of prolactin on the regulation of water, potassium and sodium. Serum prolactin levels increased significantly (P < 0.01) in group I from the control value of 6 ng/ml to 33 and 44 ng/ml when the ambient temperature was increased (weeks 3 and 4) and then decreased to 21 and 12 ng/ml after reduction in temperature during weeks 5 and 6, respectively. For group II prolactin values decreased under the treatment with the prolactin inhibitor to 0.5 ng/ml and remained at this level throughout the experiment. GH levels were unaffected by heat treatment or by treatment with prolactin inhibitor. There were no differences between groups I and II in respiratory rate, pulse rate and rectal temperature. Water intake increased in both groups under heat exposure but decreased significantly afterwards only in group II. Differences in urinary excretion volume and blood serum osmolality were not significant. Urinary potassium and sodium excretion were unchanged in group II but increased with heat exposure in group I. During heat exposure 2 bulls of group II lost weight despite maintaining food intake.

Download Full-text